At the fifth CIIE, Novartis showcased several "world's only" or "world’s first" products targeting major disease areas, including cutting-edge radioligand therapy. Radioligand therapy combines radioactive isotopes with targeted molecules, which, after intravenous injection, specifically bind to biomarkers expressed on the surface of target cells, locating tumor lesions throughout the body, emitting radiation to precisely kill target cells while causing limited damage to surrounding healthy tissues.
Novartis' Heavyweight Radioligand Therapy DrugPluvictoObtained in early last yearFDAApproved for the treatment of adult patients with prostate-specific membrane antigen-positive, metastatic castration-resistant prostate cancer.
Prostate cancer is one of the major killers endangering men's health. It is estimated that,2020Prostate cancer deaths in China reached5.1Ten thousand.
Radioligand therapy is one of the five technology platforms that Novartis focuses on. The other platforms includexRNA, Gene and Cell Therapy, Chemical and Biological Therapy.